Sentences with word «lapatinib»

The HER2 pathway is mutated in many cancers, which drives tumors, but inhibitors of this pathway, such as lapatinib, have only limited success because cancer cells quickly adapt.

Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in - licensing and clinical development of foretinib.

The investigators tested a variety of breast cancer cell types, including tamoxifen - sensitive cells that are resistant to the drug lapatinib, another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene.

Drugs like trastuzumab and lapatinib block the protein produced by the gene.

They also showed that drugs against a type of breast tumor called HER2 positive breast cancer — such as the dual ERBB2 / EGFR inhibitor lapatinib — potentially could benefit more patients than currently receive them, if analysis of the tumor proteins is taken into consideration.

«To evaluate these findings in a group with only one HER2 treatment, we are currently analyzing data from another clinical trial, the GeparQuinto clinical trial, which is a randomized, phase III clinical trial evaluating two different neoadjuvant therapy regimens with a single anti-HER2 treatment [trastuzumab or lapatinib] for women with HER2 - positive breast cancer,» said Loibl.

Dual HER2 blockade with lapatinib and trastuzumab plus AI therapy was more effective than trastuzumab plus AI alone in HER2 +, HR + metastatic breast cancer.

«Specifically, we observed a disease control rate of 96 % for trastuzumab (Herceptin)- based therapies (n = 15) and 100 % for afatinib (n = 4),» the authors wrote, adding that no responses were seen in limited data on lapatinib or masatinib.

The drug, lapatinib, activates the suppressor called FOXO, in HER2 + breast cancer cells, but then FOXO becomes a turncoat molecule, working with an epigenetic regulator that controls gene expression.

«We found that an epigenetic pathway is crucial for growth of HER2 + cells and this epigenetic factor reduces sensitivity of the cancer cells to lapatinib, a HER2 inhibitor,» said senior author Xianxin Hua, MD, PhD, a professor of Cancer Biology.

Patients with the HER2 gene are often treated with trastuzumab or lapatinib, which interfere with its cancer - causing signals.

The researchers also identified several cases with gene fusions involving the gene BCAR4, which produces a long noncoding RNA that has been shown to induce responsiveness to lapatinib, an oral drug that inhibits a key pathway in breast cancer.

Patients with HER2 - positive disease also received neoadjuvant trastuzumab and lapatinib, two HER2 - targeted therapies, while patients with triple - negative disease also received neoadjuvant bevacizumab.

Approximately 20 percent of breast cancers harbor HER2 amplification, which make these breast tumors susceptible to treatment with anti-HER2 therapies including trastuzumab and lapatinib.

«HER2 overexpression or gene amplification is widely known to be associated with sensitivity to HER2 - targeting drugs (trastuzumab, lapatinib, pertuzumab, and T - DM1) in breast cancer.»

In particular, he is focused on studying therapeutic resistance to lapatinib, a tyrosine kinase inhibitor of HER2, in breast cancer.